Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack
Stopped In view of the continuing insufficient patient recruitment in the study due to the difficult epidemiological situation and the need for rational allocation of company resources, as well as based on the results of the interim analysis.
Conditions
Interventions
- DRUG: RPH - 104
- DRUG: Voltaren®
Sponsor
R-Pharm
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]